India Technical Panel Rejects Trials Of 19 Of 47 Drugs Reviewed
This article was originally published in PharmAsia News
India's new panel for regulating clinical trials has recommended rejection of 19 of the first 47 new proposals it reviewed, including those of drug giants Novartis and Roche and local firms Cadila and Wockhardt.
You may also be interested in...
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.
One pilot target domestic manufacturers of finished drugs and another foreign manufacturers of APIs. As an incentive to participate, companies assigned high scores will be accorded regulatory flexibility. Also, participants that disclose facility ratings could “benefit from a competitive advantage.”